In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

This content is currently on FREE ACCESS, enjoy another 54 days of free consultation

In these unprecedented times, the ESC is doing everything it can to support its community: FREE access to all ESC 365 content until 31 July: explore more than 125,000 educational resources.

From 1 August onwards, support our mission by becoming a member.

Frailty as a predictor for all-cause mortality in patients 12 months after transcatheter aortic valve implantation (TAVI)

Session Poster Session III - Saturday 08:30 - 12:30

Speaker Sarah Eichler

Event : ESC Preventive Cardiology (Formerly EuroPrevent) 2017

  • Topic : arrhythmias and device therapy
  • Sub-topic : Atrial Fibrillation
  • Session type : Poster Session

Authors : S Eichler (Potsdam,DE), A Salzwedel (Potsdam,DE), A Harnath (Cottbus,DE), J Nothroff (Burg,DE), C Butter (Bernau bei Berlin,DE), M Schikora (Bernau bei Berlin,DE), M Chiorean (Rudersdorf,DE), H Voller (Potsdam,DE)

S Eichler1 , A Salzwedel1 , A Harnath2 , J Nothroff3 , C Butter4 , M Schikora5 , M Chiorean6 , H Voller1 , 1University of Potsdam, Center of Rehabilitation Research - Potsdam - Germany , 2Sana Heart Center Cottbus - Cottbus - Germany , 3MediClin Reha-Zentrum Spreewald - Burg - Germany , 4Brandenburg Heart Center - Bernau bei Berlin - Germany , 5Brandenburg Klinik - Bernau bei Berlin - Germany , 6Clinic am See, Klinik am See - Rudersdorf - Germany ,

European Journal of Preventive Cardiology ( April 2017 ) 24 ( Supplement 1 ), 150

Purpose: For more than a decade, transcatheter aortic valve implantation (TAVI) has become a promising treatment modality for patients with severe aortic stenosis. As the procedure enlarges from high-risk to lower-risk patients, the amount of patients in cardiac rehabilitation (CR) is rapidly growing. Up to now, there are no sufficient data about frailty and its possible predictive value of mortality. Therefore, we aimed to evaluate pre-interventional predictors for all-cause mortality in patients after TAVI with a 12-month follow up.
Methods: From 10/2013 to 07/2015, 344 patients with an elective TAVI were consecutively enrolled in the prospective multicentre cohort study, whereby 333 patients (80.1 ± 5.1 years, 44.1 % male) survived the procedure. Pre-interventionally, we documented sociodemographic, laboratory and echocardiographic parameters as well as comorbidities. Additionally, function by 6-minute walk test, quality of life by SF-12 and a Frailty Index (a score consisting of Activities of Daily Living, Instrumental Activities of Daily Living, Mini Mental State Exam [MMSE], Mini Nutritional Assessment [MNA], Timed Up and Go, and a subjective pre-clinical mobility disability) were performed. Predictors for all-cause mortality were identified using a multivariate regression model.
Results: During a follow up of 381.0 ± 41.9 days, 46 patients (13.8%) died. The non-survivors were older (82.3 ± 5.0 vs. 80.6 ± 5.1 years; p = 0.035), had a higher number of comorbidities (2.6 ± 1.4 vs. 2.1 ± 1.3; p = 0.026) as well as a lower left ventricular ejection fraction (51.0 ± 13.6 vs. 54.6 ± 10.6; p = 0.048) and additionally, more of the non-survivors suffered from diabetes mellitus (60.9 % vs. 44.6 %; p = 0.040). The Frailty-Index does not seem to be a predictor for all-cause mortality itself, but its single components such as MNA (OR 0.69, CI 0.70 - 0.95; p = 0.009) and MMSE (OR 0.77, CI 0.76 - 0.99; p = 0.030) show a predictive value. Furthermore, the physical component scale of SF-12 (OR = 0.90, CI 0.90 - 1.00; p = 0.031) as well as clinical parameters such as diabetes mellitus (OR 1.11, CI 1.11 - 5.29; p = 0.026) and EuroScore (OR 1.01, CI 1.01 - 1.08; p = 0.006) could be identified as predictors.
Conclusions: The results of the underlying analysis provide information about pre-interventional parameters being predictive for one-year all-cause mortality in patients after TAVI. Frailty as a whole still seems to be difficult to capture. Thus, beside clinical parameters and quality of life, single dimensions of frailty, such as cognitive function and nutrition status, should be considered in the decision of possible therapies and aftercare programs in high-risk patients with severe aortic stenosis.

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are